Dynavax Technologies Quick Ratio (DVAX) starting from the third quarter 2025 to third quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Dynavax Technologies Corporation  (NASDAQ: DVAX)

Dynavax Technologies's Quick Ratio

DVAX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Dynavax Technologies's Cash & cash equivalent grew by 5.55 % in the Q3 2025 sequentially, while Current Liabilities decreased, this led to improvement in Dynavax Technologies's Quick Ratio to 6.47, Quick Ratio remained below Dynavax Technologies Corporation average.

Within Major Pharmaceutical Preparations industry 100 other companies have achieved higher Quick Ratio than Dynavax Technologies in third quarter 2025. While Quick Ratio total ranking has improved so far during the Q3 2025 to 302, from total ranking in the second quarter 2025 at 441.

Explain Quick Ratio?
How much Cash & cash equivalents DVAX´s has?
What are DVAX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DVAX Quick Ratio (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3
Y / Y Current Liabilities Change 52.59 % 95.75 % 18.65 % 19.5 % 20.94 %
Y / Y Cash & cash equivalent Change -15.21 % -16.57 % -8.6 % -3.84 % 6.05 %
Quick Ratio MRQ 6.47 5.44 10.54 9.6 11.64
DVAX's Total Ranking # 302 # 441 # 240 # 53 # 239
Seq. Current Liabilities Change -11.2 % 79.79 % -15.61 % 13.25 % 13.92 %
Seq. Cash & cash equivalent Change 5.55 % -7.2 % -7.35 % -6.57 % 3.86 %



Quick Ratio third quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 101
Healthcare Sector # 152
Overall Market # 302


Quick Ratio Statistics
High Average Low
19.54 7.51 0.78
(Sep 30 2017)   (Sep 30 2021)




Financial Statements
Dynavax Technologies's Current Liabilities $ 100 Millions Visit DVAX's Balance sheet
Dynavax Technologies's Cash & cash equivalent $ 648 Millions Visit DVAX's Balance sheet
Source of DVAX's Sales Visit DVAX's Sales by Geography


Cumulative Dynavax Technologies's Quick Ratio

DVAX's Quick Ratio for the trailling 12 Months

DVAX Quick Ratio

 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth 46.86 % 39 % 21.52 % -0.95 % -30.06 %
Y / Y Cash & cash equivalent TTM Growth -11.09 % -5.78 % 0.24 % 5.03 % 10.72 %
Quick Ratio TTM 7.53 8.73 11.04 11.73 12.44
Total Ranking TTM # 1864 # 2375 # 2759 # 2051 # 2258
Seq. Current Liabilities TTM Growth 10.94 % 21.19 % 3.94 % 5.09 % 5.01 %
Seq. Cash & cash equivalent TTM Growth -4.22 % -4.24 % -2.12 % -0.96 % 1.49 %

Quick ratio ranking by company, industry and sector >> Back to DVAX Financial Strength Comparisons >> Go to Compare DVAX Quick Ratio to its Competitors

On the trailing twelve months basis Due to fall in Current Liabilities in the Q3 2025 to $100.14 millions, cumulative Quick Ratio decreased to 7.53 above the DVAX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 267 other companies have achieved higher Quick Ratio than Dynavax Technologies. While Quick Ratio overall ranking has improved so far to 1864, from total ranking during the twelve months ending second quarter 2025 at 2375.

Explain Quick Ratio?
How much Cash & cash equivalents DVAX´s has?
What are DVAX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 268
Healthcare Sector # 552
Within the Market # 1864


trailing twelve months Quick Ratio Statistics
High Average Low
13.2 6.31 1.03
(Mar 31 2024)   (Mar 31 2022)




Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2025 MRQ Cash & cash equivalentSep 30 2025 MRQ Current Liabilities
Climb Bio Inc   17.56 $ 86.901  Millions$ 4.949  Millions
Telomir Pharmaceuticals Inc   17.34 $ 7.329  Millions$ 0.423  Millions
Tyra Biosciences Inc   17.31 $ 274.924  Millions$ 15.879  Millions
Fulcrum Therapeutics Inc   17.25 $ 200.645  Millions$ 11.632  Millions
Ventyx Biosciences Inc   17.11 $ 192.638  Millions$ 11.259  Millions
Dianthus Therapeutics Inc   16.88 $ 402.613  Millions$ 23.855  Millions
Agios Pharmaceuticals Inc   16.78 $ 952.860  Millions$ 56.770  Millions
Arca Biopharma Inc  16.65 $ 349.155  Millions$ 20.967  Millions
Mereo Biopharma Group Plc  16.53 $ 65.859  Millions$ 3.983  Millions
Whitehawk Therapeutics Inc   16.51 $ 162.597  Millions$ 9.849  Millions
Atea Pharmaceuticals Inc   16.32 $ 329.309  Millions$ 20.175  Millions
Camp4 Therapeutics Corporation  16.18 $ 75.255  Millions$ 4.650  Millions
Synlogic Inc   16.16 $ 15.591  Millions$ 0.965  Millions
Biovie Inc   15.95 $ 24.978  Millions$ 1.566  Millions
Akero Therapeutics Inc   15.48 $ 737.826  Millions$ 47.651  Millions
Alto Neuroscience Inc   15.24 $ 137.816  Millions$ 9.045  Millions
Rezolute Inc   14.91 $ 152.194  Millions$ 10.209  Millions
Nkarta Inc   14.87 $ 282.331  Millions$ 18.988  Millions
Crinetics Pharmaceuticals Inc   14.73 $ 1,092.291  Millions$ 74.155  Millions
Eupraxia Pharmaceuticals Inc   14.52 $ 80.563  Millions$ 5.550  Millions
Oric Pharmaceuticals Inc   14.23 $ 287.140  Millions$ 20.179  Millions
Avalo Therapeutics Inc   14.01 $ 111.707  Millions$ 7.972  Millions
Arrivent Biopharma inc   13.96 $ 300.266  Millions$ 21.502  Millions
Structure Therapeutics Inc   13.89 $ 799.043  Millions$ 57.527  Millions
Kairos Pharma Ltd   13.87 $ 5.575  Millions$ 0.402  Millions
Adc Therapeutics Sa  13.86 $ 234.738  Millions$ 16.937  Millions
Bicara Therapeutics Inc   13.80 $ 290.167  Millions$ 21.028  Millions
Cryoport inc   13.77 $ 423.411  Millions$ 30.749  Millions
Pliant Therapeutics Inc   13.72 $ 241.797  Millions$ 17.624  Millions
Novabridge Biosciences  13.49 $ 32.246  Millions$ 2.391  Millions

Date modified: 2026-08-29T17:19:47+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.